Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.38, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial performance and market positioning.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock performance. The company has underperformed its sector and experienced a notable drop over the past year. Financial metrics indicate challenges, including low Return on Equity and concerns regarding debt management.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting ongoing challenges in its market performance. The company has seen a notable decline over the past year, underperforming compared to broader market indices. Financial metrics indicate weak long-term fundamentals and limited capacity to service its debt.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting ongoing challenges in the Pharmaceuticals & Biotechnology sector. The company has consistently underperformed market benchmarks, with a one-year return significantly lower than the Sensex. Weak financial metrics, including low ROE and modest sales growth, further highlight its struggles.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has consistently underperformed against market benchmarks and faces challenges in financial strength, with weak metrics in return on equity and debt servicing capabilities.

Sandu Pharmaceuticals has reached a new 52-week low, reflecting a notable decline in its stock price over the past year. The company has consistently underperformed against market benchmarks and exhibits weak long-term fundamentals, including low Return on Equity and challenges in servicing its debt obligations.

Sandu Pharmaceuticals has reached a new 52-week low, reflecting a trend of underperformance compared to its sector. The stock has declined significantly over the past year, trading below key moving averages. Concerns about the company's financial health include low return on equity and a modest growth rate in net sales.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in its stock price over the past year. The company has consistently underperformed against market benchmarks and faces challenges in long-term financial strength, with low Return on Equity and difficulties in servicing debt obligations.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant decline in the microcap company's performance within the Pharmaceuticals & Biotechnology sector. The stock has underperformed over the past year, consistently lagging behind benchmark indices and showing negative returns in recent periods, alongside weak financial metrics.

Sandu Pharmaceuticals has reached a new 52-week low of Rs. 41.01, reflecting a challenging year with a 26.40% decline in stock value. The company shows weak long-term fundamentals, with a low average Return on Equity and modest net sales growth, while the broader market experiences fluctuations.

Sandu Pharmaceuticals has hit a new 52-week low, reflecting a significant downturn in the Pharmaceuticals & Biotechnology sector. The company's stock has underperformed over the past year, with weak long-term fundamentals and limited debt management capabilities, raising concerns about its market position amid broader market declines.